Skip to main content
Endocrine Connections logoLink to Endocrine Connections
. 2021 Sep 9;10(9):X2–X3. doi: 10.1530/EC-20-0009e

Role of fasting duration and weekday in incretin and glucose regulation

Kim K B Clemmensen 1,, Jonas S Quist 1, Dorte Vistisen 1, Daniel R Witte 2,3, Anna Jonsson 4, Oluf Pedersen 4, Torben Hansen 4, Jens J Holst 4,5, Torsten Lauritzen 6, Marit E Jørgensen 1,7, Signe Torekov 4,5, Kristine Færch 1
PMCID: PMC8494403

The authors and journal apologise for errors in the above paper, which appeared in volume 9 part 4, pages 279–288. The errors relate to three values given in Table 2 on page 283. The value for Unadjusted upper 95% CI of 120 min plasma glucose should be 3.0, not 3.9, the value for Adjusted Estimate of Fasting plasma glucagon should be 0.0 not 0.3, and the value for Unadjusted Estimate of 30 min plasma GLP-1 should be −0.5 not −1.5. These errors do not affect the results or conclusions.

Table 2.

Back transformed (from log scale) estimates in percent difference for associations between overnight fasting duration and glucose, insulin, glucagon, GIP and GLP-1.

Unadjusted Adjusted for age, sex, BMI, smoking status and weekday
n Estimate (%), 95% CI P n Estimate (%), 95% CI P
Plasma glucose
 Fasting 1717 0.0 (−0.4, 0.3) 0.844 1706 −0.2 (−0.5, 0.1) 0.267
 30 min 1702 0.4 (−0.2, 0.9) 0.159 1691 0.2 (−0.3, 0.7) 0.488
 120 min 1710 2.0 (1.1, 3.0) <0.001 1699 1.7 (0.8, 2.5) <0.001
 rAUC0−30 1702 0.2 (0.0, 0.5) 0.068 1691 0.2 (0.0, 0.5) 0.109
 rAUC0−120 1698 0.9 (0.5, 1.3) <0.001 1687 0.8 (0.4, 1.2) <0.001
Plasma insulin
 Fasting 1716 1.6 (−0.3, 3.4) 0.094 1705 0.7 (−0.9, 2.2) 0.400
 30 min 1699 1.3 (−0.6, 3.3) 0.172 1688 0.7 (−1.2, 2.5) 0.481
 120 min 1708 4.8 (2.3, 7.2) <0.001 1697 3.6 (1.4, 5.8) 0.001
 rAUC0−30 1698 0.0 (−1.5, 1.4) 0.957 1687 0.2 (−1.2, 1.6) 0.805
 rAUC0−120 1694 1.2 (−0.2, 2.7) 0.084 1683 1.3 (−0.1, 2.7) 0.066
Plasma glucagon
 Fasting 1466 0.5 (−1.4, 2.5) 0.601 1455 0.0 (−1.8, 1.9) 0.967
 30 min 1453 2.0 (0.0, 4.0) 0.048 1442 1.0 (−0.8, 2.9) 0.278
 120 min 1457 −0.4 (−3.0, 2.3) 0.783 1446 −0.8 (−3.4, 1.9) 0.553
 rAUC0−30 1450 0.2 (−0.5, 1.0) 0.579 1439 0.0 (−0.7, 0.8) 0.903
 rAUC0−120 1442 0.2 (−0.9, 1.4) 0.720 1431 0.0 (−1.1, 1.2) 0.972
Plasma GIP
 Fasting 1402 −2.6 (−4.3, −0.9) 0.003 1391 −2.4 (−4.1, −0.7) 0.006
 30 min 1390 0.5 (−0.9, 1.9) 0.511 1380 0.5 (−0.9, 1.9) 0.468
 120 min 1394 0.4 (−1.0, 1.8) 0.552 1383 0.7 (−0.7, 2.0) 0.328
 rAUC0−30 1386 2.7 (1.2, 4.3) <0.001 1376 2.6 (1.1, 4.1) 0.001
 rAUC0−120 1377 3.0 (1.4, 4.7) <0.001 1367 3.0 (1.3, 4.7) 0.001
Plasma GLP-1
 Fasting 1464 −2.3 (−4.6, 0.0) 0.046 1453 −2.9 (−5.1, −0.6) 0.013
 30 min 1453 −0.5 (−2.5, 1.5) 0.601 1442 −0.9 (−2.8, 1.0) 0.358
 120 min 1457 −0.8 (−2.4, 0.9) 0.380 1446 −0.7 (−2.3, 0.9) 0.388
 rAUC0−30 1448 1.4 (−0.5, 3.2) 0.149 1437 1.6 (−0.3, 3.4) 0.093
 rAUC0−120 1440 1.9 (−0.2, 4.0) 0.073 1429 2.3 (0.3, 4.4) 0.026

Estimates are per 1 h increase in fasting duration. Linear regression models.

GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; rAUC0–30, relative early response; rAUC0–120, relative total response.

The correct Table 2 is given in full below:


Articles from Endocrine Connections are provided here courtesy of Bioscientifica Ltd.

RESOURCES